title: Non-steroidal anti-inflammatory drug use and brain tumour risk: a case-control study within the Clinical Practice Research Datalink.
abstract: OBJECTIVE
  The aetiology of primary brain tumours is largely unknown; the role of non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin use and glioma risk has been inconclusive, but few population-based studies with reliable prescribing data have been conducted, and the association with meningioma risk has yet to be assessed.
  
  
  METHODS
  The UK Clinical Practice Research Datalink was used to assess the association between aspirin and non-aspirin NSAID use and primary brain tumour risk using a nested case-control study design. Conditional logistic regression analysis was performed on 5,052 brain tumour patients aged 16 years and over, diagnosed between 1987 and 2009 and 42,678 controls matched on year of birth, gender and general practice, adjusting for history of allergy and hormone replacement therapy use in the glioma and meningioma models, respectively.
  
  
  RESULTS
  In conditional logistic regression analysis, excluding drug use in the year preceding the index date, there was no association with non-aspirin NSAID use (OR 0.96, 95 % CI 0.81-1.13) or glioma risk comparing the highest category of daily defined dose to non-users; however, non-aspirin NSAID use was positively associated with meningioma risk (OR 1.35, 95 % CI 1.06-1.71). No association was seen with high- or low-dose aspirin use irrespective of histology.
  
  
  CONCLUSIONS
  This large nested case-control study finds no association between aspirin or non-aspirin NSAID use and risk of glioma but a slight increased risk with non-aspirin NSAIDs and meningioma.
authors.affiliation: Northern Ireland Cancer Registry, Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK, f.j.bannon@qub.ac.uk.
authors.forename: F J
authors.initials: FJ
authors.lastname: Bannon
authors.forename: M A
authors.initials: MA
authors.lastname: O'Rorke
authors.forename: L J
authors.initials: LJ
authors.lastname: Murray
authors.forename: C M
authors.initials: CM
authors.lastname: Hughes
authors.forename: A T
authors.initials: AT
authors.lastname: Gavin
authors.forename: S J
authors.initials: SJ
authors.lastname: Fleming
authors.forename: C R
authors.initials: CR
authors.lastname: Cardwell
mesh_terms: D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001241:Aspirin / Q000009:adverse effects; D001932:Brain Neoplasms / Q000139:chemically induced*; D016022:Case-Control Studies; D005260:Female; D005910:Glioma / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008577:Meningeal Neoplasms / Q000139:chemically induced; D008579:Meningioma / Q000139:chemically induced; D008875:Middle Aged; D016017:Odds Ratio; D018570:Risk Assessment / Q000379:methods / Q000706:statistics & numerical data; D012307:Risk Factors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin